HCPCS Code Details - C9093

HCPCS Level II Code
Temporary Codes for Use with Outpatient Prospective Payment System
HCPCS Code C9093

Long description:
Injection, ranibizumab, via sustained release intravitreal implant (susvimo), 0.1 mg

Short description:
Inj., susvimo, 0.1 mg

HCPCS Modifier1
HCPCS Pricing indicator 53 - Statute
Multiple pricing indicator A - Not applicable as HCPCS priced under one methodology
Statute number 1833(t)
Coverage code D - Special coverage instructions apply
BETOS2 code O1E - Other drugs
HCPCS Action code D - Discontinue procedure or modifier code
Type of service 9 - Other medical items or services
Effective date Effective Jul 01, 2022
Date added Added Apr 01, 2022
Termination date Jun 30, 2022
HCPCS Coding Procedures
  HCPCS Code C9093 has been discontinued effective Jul 01, 2022.

HCPCS Modifiers

In HCPCS Level II, modifiers are composed of two alpha or alphanumeric characters.

Example: E0260-NU - Hospital bed, semi-electric (head and foot adjustment), with any type side rails, with mattress
NU” identifies the hospital bed as new equipment

See also

  • HCPCS C9092 · Injection, triamcinolone acetonide, suprachoroidal (xipere), 1 mg

  • HCPCS J2779 · Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg

  • HCPCS C9094 · Inj, sutimlimab-jome, 10 mg

1 Two-digit numeric codes are Level I code modifiers copyrighted© by the American Medical Association's Current Procedural Terminology (CPT).

2 BETOS stands for “Berenson-Eggers Type Of Service”